Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2020 14:35 ET | Source: Merus N.V.

Merus und myTomorrows kündigen Ausbau ihrer Zusammenarbeit an, um Aufmerksamkeit für Screening und klinische eNRGy-Studie zur Behandlung von Krebspatienten mit Tumoren mit Neuregulin-1-Fusionen zu erhöhen

UTRECHT, Niederlande, und CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- myTomorrows, ein globales Unternehmen im Bereich Gesundheitstechnologien, und Merus N.V. (Nasdaq: MRUS), ein Unternehmen...
October 13, 2020 14:35 ET | Source: Merus N.V.

Merus et myTomorrows annoncent l'extension de leur collaboration pour le dépistage et la sensibilisation à l'essai clinique eNRGy pour les patients atteints d'un cancer avec des tumeurs à fusion du gène neuréguline 1

UTRECHT, Pays-Bas, et CAMBRIDGE, Massachusetts, 13 oct. 2020 (GLOBE NEWSWIRE) -- myTomorrows, entreprise mondiale spécialisée dans les technologies de la santé, et Merus N.V. (Nasdaq : MRUS),...
October 12, 2020 17:00 ET | Source: Merus N.V.

Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company...
July 10, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer

PHILADELPHIA, July 10, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen...
January 26, 2017 10:51 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe

PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access...
January 11, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

PHILADELPHIA, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that the rintatolimod European early access program (EAP) designed...
August 10, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Enters Into an Agreement With myTomorrows for an Early Access Program for Rintatolimod in Europe

PHILADELPHIA, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Impatients, N.V., a...